Biomea Fusion Engages in Investor Conferences
Biomea Fusion, Inc. (Nasdaq: BMEA), a leading clinical-stage company in the field of diabetes and obesity treatment, recently announced its participation in several important upcoming investor conferences. This is an exciting opportunity for Biomea to showcase its ongoing developments and further engage with the investment community.
Upcoming Conference Participation
Piper Sandler 37th Annual Healthcare Conference
Biomea will take part in a fireside chat scheduled for 8:00 AM (EST) on December 2, in a vibrant New York setting. This participation highlights their commitment to discussing the evolving landscape of diabetes and obesity treatments. Additionally, one-on-one meetings will be held, offering more personal engagement with attendees.
Evercore Healthcare Conference
The following day, on December 3, Biomea is set to feature at the 8th Annual Evercore Healthcare Conference at 7:30 AM (EST) in Coral Gables. Here, they will also engage in one-on-one meetings, fostering deeper connections and providing insights into their promising pipeline.
Audio Webcasts and Replay Information
For those unable to attend in person, Biomea will offer an audio webcast of both presentations. Interested parties can find the webcasts on the company's official website and the News & Events page, allowing for access and review of these significant discussions. A replay will be available following the live events for further convenience.
About Biomea Fusion
Biomea Fusion is at the forefront of biopharmaceutical innovation, focusing on creating oral small molecule therapies aimed at treating diabetes and obesity. Their lead candidates involve icovamenib, a selective menin inhibitor designed particularly for diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist targeting obesity. These initiatives specifically address the pressing issue of cardio-metabolic disorders that currently affect a substantial portion of the global population, including millions across America.
The company’s mission is clear: to develop transformative treatments that improve the lives of patients battling diabetes, obesity, and other related health challenges. Biomea Fusion strives not just for treatment, but aims for cures, pushing the boundaries of what is possible in the field.
For more information about Biomea Fusion and their innovative products, visit biomeafusion.com and follow their updates on LinkedIn, Twitter, and Facebook.
Contact Information
For any inquiries, you can reach out to Meichiel Jennifer Weiss, the Senior Director of Investor Relations and Corporate Development, via email at ir@biomeafusion.com.
Frequently Asked Questions
What is Biomea Fusion?
Biomea Fusion is a clinical-stage biopharmaceutical company dedicated to developing therapies for diabetes and obesity.
When will Biomea Fusion participate in the investor conferences?
Biomea Fusion will participate in upcoming investor conferences on December 2 and December 3.
What therapies is Biomea currently developing?
Biomea is advancing icovamenib for diabetes and BMF-650 for obesity.
How can I access the conference presentations?
Audio webcasts of the presentations will be available on Biomea's official website.
Who should I contact for investor relations?
You can contact Meichiel Jennifer Weiss for investor inquiries at ir@biomeafusion.com.
